Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

72.50 +2.37 (+3.38%)
Delayed Quote Updated: 10:45 AM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near ↗
Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president... 
Via MarketBeat
News headline image
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
From Exelixis, Inc.
Via Business Wire
News headline image
GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal ↗
NCR Atleos delivers self-service banking technology and managed services to financial institutions and enterprise clients worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
EXELIXIS INC (NASDAQ:EXEL) Presents a Compelling Case for Value Investors ↗
Via Chartmill
Exelixis Beats Q1 Estimates and Advances Pipeline, Driving EXEL Momentum ↗
Via Chartmill
News headline image
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Prediction: This Stock Could Double By 2031 ↗
It's not the most prominent company in its industry, but it is definitely worth a second look. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis (EXEL) Q1 2026 Earnings Transcript ↗
Exelixis (EXEL) Q1 2026 Earnings Transcript 
Via The Motley Fool
Exelixis Inc (NASDAQ:EXEL) Passes the Caviar Cruise Quality Screen with Zero Debt and 54% ROIC ↗
Via Chartmill
News headline image
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗
These companies boast significant upside potential. 
Via The Motley Fool
Exelixis Inc. (NASDAQ:EXEL) Presents a Compelling Value Investment Case ↗
Via Chartmill
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case ↗
Via Chartmill
Exelixis Inc. (NASDAQ:EXEL) Stands Out as a Quality Investing Candidate ↗
Via Chartmill
Exelixis Inc (NASDAQ:EXEL) Reports Mixed Q4 2025 Results, Beats on EPS but Misses on Revenue ↗
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) Combines Strong Growth Fundamentals with Bullish Technical Setup ↗
Via Chartmill
News headline image
Exelixis: A Strong Contender in the Cancer Drug Market ↗
Could Exelixis be the next big player in cancer treatment? Join us as we explore its potential and the risks involved in this exciting investment opportunity. 
Via The Motley Fool
News headline image
The Best Healthcare Stocks to Buy With $50 Right Now ↗
Even on a budget, you can get quality stocks. 
Via The Motley Fool
News headline image
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗
The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other biotherapeutics. 
Via The Motley Fool
Topics Lawsuit
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026 ↗
The stock is coming off a strong year. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Exelixis Reports Solid Earnings—Are New Highs Back on the Table? ↗
Via MarketBeat
News headline image
Exelixis (EXEL) Q4 2025 Earnings Call Transcript ↗
Exelixis (EXEL) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
2 Stocks That Could Soar This Year ↗
These innovative biotechs could have plenty of upside ahead. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
From Exelixis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.